| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
T Cells1
*
Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, and
Multidisciplinary Oncology Center, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland;
Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO; and
Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Epalinges, Switzerland
The membrane receptor 2B4 is a CD2 family member that is involved
in lymphocyte activation. A fraction of human CD8+ 
T
cells up-regulate 2B4 in vivo, and here we demonstrate that this
correlates with the acquisition of effector cell properties such as
granzyme B and perforin expression, rapid IFN-
production, and
down-regulation of the lymph node homing chemokine receptor CCR7. In
PBLs from healthy donors, cytomegalovirus-specific effector T cells
were 2B4 positive, whereas naive melanoma Ag (Melan-A/melanoma Ag
recognized by T cells-1)-specific T cells were 2B4 negative. In
melanoma patients, Melan-A-specific T cells up-regulated 2B4 in
parallel with in vivo differentiation. This occurred in PBLs after
vaccination with Melan-A peptides and in tumor-infiltrated lymph nodes,
likely through disease-associated activation of Melan-A-specific T
cells. Thus, 2B4 expression correlates with CD8+ T cell
differentiation in vivo.
This article has been cited by other articles:
|
|
 |
|
  T. J. Wilson, R. M. Presti, I. Tassi, E. T. Overton, M. Cella, and M. Colonna FcRL6, a new ITIM-bearing receptor on cytolytic cells, is broadly expressed by lymphocytes following HIV-1 infection Blood, May 1, 2007; 109(9): 3786 - 3793. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. B. Frey and N. Monu Effector-phase tolerance: another mechanism of how cancer escapes antitumor immune response J. Leukoc. Biol., April 1, 2006; 79(4): 652 - 662. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Morandi, R. Costa, M. Falco, S. Parolini, A. De Maria, G. Ratto, M. C. Mingari, G. Melioli, A. Moretta, and G. Ferlazzo Distinctive Lack of CD48 Expression in Subsets of Human Dendritic Cells Tunes NK Cell Activation J. Immunol., September 15, 2005; 175(6): 3690 - 3697. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Eissmann, L. Beauchamp, J. Wooters, J. C. Tilton, E. O. Long, and C. Watzl Molecular basis for positive and negative signaling by the natural killer cell receptor 2B4 (CD244) Blood, June 15, 2005; 105(12): 4722 - 4729. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Dupre, G. Andolfi, S. G. Tangye, R. Clementi, F. Locatelli, M. Arico, A. Aiuti, and M.-G. Roncarolo SAP controls the cytolytic activity of CD8+ T cells against EBV-infected cells Blood, June 1, 2005; 105(11): 4383 - 4389. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Monsurro, E. Wang, Y. Yamano, S. A. Migueles, M. C. Panelli, K. Smith, D. Nagorsen, M. Connors, S. Jacobson, and F. M. Marincola Quiescent phenotype of tumor-specific CD8+ T cells following immunization Blood, October 1, 2004; 104(7): 1970 - 1978. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Loza and B. Perussia The IL-12 Signature: NK Cell Terminal CD56+high Stage and Effector Functions J. Immunol., January 1, 2004; 172(1): 88 - 96. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Dhanji and H.-S. Teh IL-2-Activated CD8+CD44high Cells Express Both Adaptive and Innate Immune System Receptors and Demonstrate Specificity for Syngeneic Tumor Cells J. Immunol., October 1, 2003; 171(7): 3442 - 3450. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Konno, K. Okada, K. Mizuno, M. Nishida, S. Nagaoki, T. Toma, T. Uehara, K. Ohta, Y. Kasahara, H. Seki, et al. CD8alpha alpha memory effector T cells descend directly from clonally expanded CD8alpha +beta high TCRalpha beta T cells in vivo Blood, December 1, 2002; 100(12): 4090 - 4097. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
